

Studies on the Regioselectivity of the Cyclization of Tryptophan-Derived Oxazolopiperidone Lactams

Mercedes Amat,^{*,[a]} Núria Llor,^[a] Fabiana Subrizi,^[a] Maria Pérez,^[a] Elies Molins,^[b] and Joan Bosch^[a]

Keywords: Lactams / Asymmetric synthesis / Cyclization / Bischler–Napieralski / α -Amidoalkylation


Cyclization of the lactam carbonyl on the indole ring in tryptophan-derived oxazolopiperidone lactams **2** and **6**, under the classical POCl₃-promoted Bischler–Napieralski conditions and under neutral conditions via the corresponding thiolactam, is

studied. Whereas tricyclic lactam **2** only leads to products coming from an α -amidoalkylation process, bicyclic lactam **6** undergoes cyclization on the lactam carbonyl, leading to the expected indolo[2,3-*a*]quinolizidine derivatives.

Introduction

Tryptophan-derived oxazolopiperidone lactams have proven to be versatile chiral building blocks for the enantioselective synthesis of indole alkaloids.^[1] These lactams are easily accessible in enantiopure form in a single synthetic step by a stereoselective cyclocondensation reaction between (*S*)-tryptophan and an appropriate δ -oxo acid derivative.^[2] Tryptophan not only constitutes the source of chirality but can also be used in subsequent steps to assemble complex polycyclic targets by regio- and stereocontrolled cyclization reactions on the indole ring.

Taking advantage of the functionalization present in the oxazolopiperidone lactam, an electrophilic cyclization on the indole 2-position can involve either the hemiaminal ether carbon via an *N*-acyliminium cation (via **a**)^[1a-d,2] or the lactam carbonyl via a Bischler–Napieralski-type reaction (via **b**),^[1e,3] leading to regioisomeric indolo[2,3-*a*]quinolizidines (when R₁ \neq H). Additionally, by choosing the appropriate reaction conditions, the intramolecular α -amidoalkylation allows the stereocontrolled generation of C-12b epimeric derivatives. On the other hand, a Lewis acid/Et₃SiH-promoted cyclization on the indole 3-position from *N*_α-tosyl derivatives provides straightforward access to the spiro[indole-3,1'-indolizidine] framework^[4] present in a large number of alkaloids (via **c**). These complementary types of cyclization are shown in Scheme 1.




Scheme 1. Regio- and stereocontrolled cyclizations from (*S*)-tryptophan-derived oxazolopiperidone lactams.

Although there are many examples of acid-promoted intramolecular α -amidoalkylation reactions from (*S*)-tryptophan-derived oxazolopiperidone lactams, cyclizations involving the lactam carbonyl have been little explored. In fact, our initial attempts to perform a Bischler–Napieralski cyclization under the classical conditions (POCl₃, then NaBH₄) were unsuccessful^[1e,5] due to the tendency of these lactams to undergo acid-promoted intramolecular α -amidoalkylation reactions. However, the desired cyclization on the lactam carbonyl can be satisfactorily performed under non-acidic conditions by a modified Bischler–Napieralski procedure via a (benzylthio)iminium intermediate.^[1e] In the only example reported to date of a successful POCl₃-promoted Bischler–Napieralski cyclization from a tryptophan-derived oxazolopiperidone lactam,^[3] the hemiaminal ether carbon incorporates an additional substituent, which, for steric reasons, seems to hamper the intramolecular α -amidoalkylation reaction.

[a] Laboratory of Organic Chemistry, Faculty of Pharmacy, and Institute of Biomedicine (IBUB), University of Barcelona, Av. Joan XXIII s/n, 08028 Barcelona, Spain
Fax: (+34) 934-024-539
E-mail: amat@ub.edu

[b] Institut de Ciència de Materials de Barcelona (CSIC), Campus UAB, 0 8193 Cerdanyola, Spain

Supporting information for this article is available on the WWW under <http://dx.doi.org/10.1002/ejoc.xxxxxxxx>




Scheme 2. Studies on the synthesis of normalindine. Cyclization under Bischler–Napieralski conditions.

Results and Discussion

With these precedents in mind, we decided to explore if the methodology could be applied to the synthesis of malindine alkaloids, for instance normalindine,^[6] which are characterized by the presence of a partially reduced 1-methyl-2,7-naphthyridine moiety (Scheme 2). The synthesis would involve as the key steps a cyclocondensation reaction between (*S*)-tryptophan and pyridine δ -keto ester **1**, a Bischler–Napieralski cyclization from the resulting tricyclic lactam, and finally, the reductive opening of the oxazolidine ring with subsequent removal of the hydroxymethyl appendage.^[7] The quaternary carbon 10b on the oxazolidine ring would hamper the α -amidoalkylation process in favor of the Bischler–Napieralski cyclization.

As foreseen, the cyclocondensation reaction took place in acceptable yield (65%) and excellent stereoselectivity to give the *trans* 3-*H*/10b-*Me* 2,7-naphthyridine lactam **2**.^[8] However, rather unexpectedly, treatment of this lactam under classical Bischler–Napieralski conditions (POCl_3 , then NaBH_4) resulted in an α -amidoalkylation process, leading to hexacycle **3** (42% yield) and pentacycle **4** (21% yield). No products coming from the cyclization of the lactam carbonyl on the indole ring were detected.

The formation of **3** can be rationalized by considering a rapid generation of an *N*-acyliminium cation^[9] and its cyclization on the indole ring, a subsequent interaction of the hydroxymethyl substituent with the chloroiminium intermediate generated from the lactam carbonyl, and a final reduction by NaBH_4 of the resulting oxazolinium salt.^[10] A further reduction, with opening of the oxazolidine ring, would lead to **4**.




Scheme 3. Reaction of lactam **2** with Lawesson's reagent.

The *cis* 1-*Me*/3-*H* relative stereochemistry for the tetrahydro- β -carboline moiety, established by NOE experiments, probably results from an acid-promoted epimerization^[11] of the quaternary stereocenter initially formed in the cyclization,^[12] driven by the generation of a *cis* oxazolinium intermediate, **A**. A final stereoelectronically controlled^[13] axial attack of the hydride installs the all-*cis* relative configuration of **3**.

To avoid the undesirable acid-promoted α -amidoalkylation reaction, we decided to perform a Bischler–Napieralski-type cyclization under neutral conditions^[1e] from the thiolactam derived from **2**. Surprisingly, treatment of lactam **2** with Lawesson's reagent led in excellent yield (81%) to the hexacyclic thioderivative **5** instead of the expected thiolactam (Scheme 3). The formation of **5** can be accounted for by considering that, once the thiolactam was formed, the generation of the *N*-thioacyl iminium ion **B** was facilitated by the lower electronegativity of the sulfur atom. Cyclization on the indole ring would afford pentacyclic intermediate **C**. A subsequent cyclization via the *O*-alkyl phenylphosphonodithioic acid intermediate **D**^[14] would lead to **5**.

The above results indicate that an acidic environment is not the only factor to favor the competitive α -amidoalkylation reaction. Most probably, due to the presence of the fused π -deficient pyridine, the benzylic character of the *N*-acyl (or thioacyl) iminium species generated by the opening of the oxazolidine ring also plays an important role.

To gain further insight into the factors governing the regioselectivity of the cyclization on the carbonyl group of tryptophan-derived oxazolopiperidone lactams, we decided to study the Bischler–Napieralski cyclization from a model lactam **6**, which lacks the pyridine ring present in **2**. This lactam was prepared by cyclocondensation between (*S*)-tryptophanol and 5-oxohexanoic acid. Under the usual reaction conditions (toluene, reflux), a mixture of **6** and its 8*a*-epimer (80% yield, 87:13 ratio) was obtained^[15] (Scheme 4). A more convenient experimental procedure involved the use of microwaves:^[16] irradiation of an equimolar mixture of the starting materials for 10 min at 110 °C provided a 92:8 diastereoisomeric mixture of **6** and its 8*a*-epimer in 77% yield, with only traces of the cyclized product **9** (Scheme 5) being detected.



Scheme 4. Cyclizations on the lactam carbonyl from lactams **6**.

As expected, cyclization on the lactam carbonyl took place satisfactorily from lactams **6**, not only under neutral conditions via a thiolactam but also under the classical POCl_3 -promoted Bischler–Napieralski conditions. Thus, the epimeric mixture of **6** was converted to the corresponding thiolactams (54%), which were treated with benzyl bromide and then NaBH_4 , to regio- and stereoselectively give (51%) a single pentacyclic indoloquinolizidine derivative **7**. Similarly, treatment of the epimeric mixture of **6** with POCl_3 and then NaBH_4 stereoselectively led to a 3:2 mixture of pentacycle **7** and indoloquinolizidine **8** in 52% overall yield.^[17] The former was quantitatively converted to **8** by additional treatment with NaBH_4 .^[18]

The all-*cis* stereochemistry of **7**, established by NOE experiments (4-Me/6-H, 4-Me/12b-H, and 6-H/12b-H), deserves some comment as the stereocenters bearing the methyl substituent in the major starting lactam **6** and in the cyclized product **7** have the opposite relative configuration. This indicates that during the above cyclization an equilibration has occurred via an open oxazolidine intermediate, ultimately leading to the less strained *cis* 4-Me/6-H iminium salt **E** (Figure 1), which undergoes a final stereoelectronically controlled^[13] axial attack of the hydride. Finally, also worthy of comment is the inversion of the configuration during the reductive opening of the oxazolidine ring to give **8**, once again involving a stereoelectronically controlled

attack of the hydride on the less hindered face of the intermediate iminium species **F**.





Figure 1. Stereocontrolled reduction of iminium ion intermediates.

The above successful Bischler–Napieralski-type cyclizations make evident that the intramolecular α -amidoalkylation process is slowed down by the presence of the additional substituent at the 2-position of the oxazolidine ring. In fact, lactams **6** were recovered unchanged (only trace amounts of the cyclized product **9** were detected) after treatment with HCl (0.6 M in EtOH, rt, 24 h), whereas these reaction conditions promote a clean and highly stereoselective α -amidoalkylation (95% yield) when applied to the corresponding lactams lacking the angular methyl substituent.^[5] Under more drastic conditions (1.25 M HCl in EtOH, 70 °C, 72 h), cyclization of **6** took place in good yield (70%) but with a low stereoselectivity to give a nearly 1:1 mixture of *trans* and *cis* indoloquinolizidines **10** and 12*b*-*epi*-**9**, probably because the strong acidity causes the epimerization at C-12b of the indolo[2,3-*a*]quinolizidine system^[12] (Scheme 5). From the synthetic standpoint, the best results were obtained using a 0.9 M solution of TFA in CH_2Cl_2 (rt, 20 h), since a 4:1 stereoisomeric mixture of indoloquinolizidines **9** and 12*b*-*epi*-**9** was obtained in 86% yield. The absolute configuration of the cyclized products **9** and 12*b*-*epi*-**9** was unambiguously determined by X-ray crystallographic analysis.^[19]



Scheme 5. α -Amidoalkylation reaction from lactams **6**.

The stereoselective formation of **9** leading to a *trans* 6-H/12*b*-Me stereochemistry can be rationalized by analyzing the two

possible reactive chair-like conformations (**X** and **Y**; R= Me) of the intermediate *N*-acyliminium cation.^[9] Cyclization takes place faster from conformation **X**, which avoids the severe A^(1,3) strain between the hydroxymethyl substituent and the lactam carbonyl group in the transition state.^[20] The lower stereoselectivity in the cyclization of **6** compared with that of the corresponding demethyl lactam^[2a,5] can be explained by the stronger A^(1,3) CH₂OH/R strain present in the conformation **X** when R= Me than when R= H.

Conclusions

Although under the classical POCl₃-promoted Bischler–Napieralski reaction conditions tryptophan-derived oxazolopiperidone lactams unsubstituted at the hemiaminal ether carbon (*i.e.* generated from aldehyde-esters) undergo an intramolecular α -amidoalkylation reaction instead of the expected cyclization on the lactam carbonyl, lactams substituted at this position (*e.g.* **6**, derived from a ketone-ester) successfully undergo a regioselective Bischler–Napieralski cyclization on the lactam carbonyl, avoiding the competitive α -amidoalkylation process.

The unexpected behavior of tricyclic lactam **2**, which exclusively leads to products coming from an α -amidoalkylation process, is a consequence of the presence of the fused π -deficient pyridine ring that originates a reactive benzylic-type *N*-acyl (or thioacyl) iminium ion.

Experimental Section

General: Flash chromatography was carried out on SiO₂ (silica gel 60, SDS, 35–70 μ m or using Biotage[®] SNAP cartridges, 50 μ m). Optical rotations were measured on Perkin-Elmer 241 polarimeter. High resolution mass spectra (HMRS; LC/MSD TOF Agilent Technologies) were performed by Centres Científics i Tecnològics de la Universitat de Barcelona. Microanalyses (Carlo Erba 1106 analyzer) were performed by Centre d'Investigació i Desenvolupament (CSIC), Barcelona. Only noteworthy IR absorptions (cm⁻¹; Nicolet Avantar 320 FT-IR) are listed. NMR spectra were recorded at 400 MHz (¹H) and 75.4 or 100.6 MHz (¹³C).

(3S,10bR)-3-(3-Indolylmethyl)-5-oxo-2,3,6,10b-tetrahydro-5H-oxazolo[2,3-*a*][2,7]naphthyridine (2): (*S*)-tryptophanol (228 mg, 1.2 mmol) and isobutyric acid (132 mg, 1.5 mmol) were added to a solution of compound **1**^[21] (200 mg, 1 mmol) in toluene (16 mL). The mixture was heated at reflux for 19 h with azeotropic elimination of water by a Dean-Stark system. The resulting mixture was cooled and concentrated under reduced pressure. The residue was dissolved in CH₂Cl₂ and the solution was washed twice with saturated aqueous NaHCO₃ solution. The organic phase was dried, filtered, and concentrated. Flash chromatography (2:8 hexane/EtOAc) gave lactams **2** and 10b-*epi*-**2** as a 96:4 mixture (218 mg, 65%).

Data for 2 (from the mixture): ¹H NMR (400 MHz, CDCl₃, COSY, HSQC, 25 °C): δ = 1.52 (s, 3H, CH₃), 3.16 (dd, *J* = 14.0, 10.0 Hz, 1H, CH₂), 3.50 (dd, *J* = 14.0, 3.6 Hz, 1H, CH₂), 3.58 (d, *J* = 18.4 Hz, 1H, H-6), 3.73 (d, *J* = 18.4 Hz, 1H, H-6), 3.93 (dd, *J* = 8.6, 6.4 Hz, 1H, H-2), 4.09 (dd, *J* = 8.6, 4.8 Hz, 1H, H-2), 4.60 (m, 1H, H-

3), 7.11 (d, *J* = 2.0 Hz, 1H, H-2'), 7.15 (masked d, 1H, H-7), 7.16 (td, *J* = 8.0, 1.2 Hz, 1H, H-6'), 7.21 (td, *J* = 7.2, 1.2 Hz, 1H, H-5'), 7.37 (d, *J* = 8.0 Hz, 1H, H-7'), 7.80 (d, *J* = 7.2 Hz, 1H, H-4'), 8.32 (br. s, 1H, NH), 8.52 (br. s, 1H, H-8), 8.69 (br. s, 1H, H-10) ppm. ¹³C NMR (100.6 MHz, CDCl₃, 25 °C): δ = 28.2 (CH₃), 28.5 (CH₂), 37.6 (C-6), 56.5 (C-3), 69.1 (C-2), 92.8 (C-10b), 111.2 (C-7'), 111.6 (C-3a'), 119.1 (C-4'), 119.8 (C-6'), 121.9 (C-7), 122.3 (C-5'), 122.5 (C-2'), 127.6 (C-7a'), 136.2 (C-10a), 139.1 (C-6a), 144.7 (C-10), 149.4 (C-8), 165.6 (CO) ppm. IR (NaCl): ν = 1411, 1651, 3292 cm⁻¹. HRMS: calcd. for C₂₀H₂₀N₃O₂ [M + H]⁺: 334.1550; found: 334.1552.

Data for 10b-*epi*-2 (from an enriched mixture): ¹H NMR (400 MHz, CDCl₃, 25 °C): δ = 1.54 (s, 3H, CH₃), 2.63 (dd, *J* = 14.0, 10.0 Hz, 1H, CH₂), 3.61 (dd, *J* = 14.0, 2.8 Hz, 1H, CH₂), 3.62 (d, *J* = 19.2 Hz, 1H, H-6), 3.72 (d, *J* = 19.2 Hz, 1H, H-6), 4.20 (dd, *J* = 9.6, 2.0 Hz, 1H, H-2), 4.24 (dd, *J* = 9.6, 1.2 Hz, 1H, H-2), 4.49 (dddd, *J* = 10.0, 5.2, 2.8, 2.8 Hz, 1H, H-3), 6.97 (d, *J* = 2.0 Hz, 1H, H-2'), 7.10–7.22 (masked m, 3H, H-7, H-5', H-6'), 7.29 (br. d, *J* = 8.0 Hz, 1H, H-7'), 7.75 (d, *J* = 7.6 Hz, 1H, H-4'), 8.16 (br. s, 1H, NH), 8.52 (masked d, 1H, H-8), 8.65 (br. s, 1H, H-10) ppm. NOESY 1D: positive NOE effect: 3-H/10b-Me.

Treatment of 2 under Bischler–Napieralski conditions: POCl₃ (373 μ L, 4.08 mmol) was added to a solution of lactams **2** and *epi*-**2** (100 mg, 0.3 mmol) in toluene (3.8 mL), and the mixture was heated at 100 °C for 1.5 h. After cooling, the solvent was removed and the resulting brown residue was dissolved in anhydrous MeOH (6 mL). Then, NaBH₄ (136 mg, 3.6 mmol) was slowly added to the solution at 0 °C, and the mixture was allowed to reach room temperature for 2 h and refluxed for 2.5 h. The mixture was cooled at 0 °C and quenched by addition of saturated aqueous NaHCO₃. The solvent was evaporated, and the resulting residue was dissolved in CH₂Cl₂. The organic phase was washed with brine, dried, and concentrated. Flash chromatography of the residue (95:5 CH₂Cl₂/MeOH) afforded hexacycle **3** (40 mg, 42%) and pentacycle **4** (20 mg, 21%).

Data for 3: Yellow oil. [α]_D²² = -101.5 (*c* = 0.9, CHCl₃). ¹H NMR (400 MHz, CDCl₃, COSY, HSQC, 25 °C): δ = 2.02 (s, 3H, CH₃), 2.90 (ddd, *J* = 15.2, 9.2, 0.8 Hz, 1H, H-5), 2.97 (dd, *J* = 16.5, 7.6 Hz, 1H, H-9), 3.04 (dd, *J* = 16.5, 9.2 Hz, 1H, H-9), 3.13 (dd, *J* = 15.2, 3.2 Hz, 1H, H-5), 4.02 (d, *J* = 6.8 Hz, 1H, CH₂O), 4.22 (m, 1H, H-8), 4.29 (dd, *J* = 6.8, 4.8 Hz, 1H, CH₂O), 4.57 (dd, *J* = 9.2, 3.2 Hz, 1H, H-6), 7.10 (masked d, 1H, H-4), 7.10 (masked td, 1H, H-11), 7.15 (td, *J* = 7.2, 1.2 Hz, 1H, H-12), 7.30 (d, *J* = 8.0 Hz, 1H, H-10), 7.47 (d, *J* = 7.2 Hz, 1H, H-13), 8.37 (d, *J* = 4.8 Hz, 1H, H-3), 8.95 (br. s, 1H, NH), 9.19 (s, 1H, H-1) ppm. NOESY 1D: positive NOE effect: 1-Me/3-H. ¹³C NMR (100.6 MHz, CDCl₃, 25 °C): δ = 21.9 (C-9), 31.7 (CH₃), 36.3 (C-5), 50.9 (C-8), 56.9 (C-14b), 72.3 (CH₂O), 83.1 (C-6), 104.7 (9a), 111.2 (C-13), 118.2 (C-10), 119.7 (C-11), 122.2 (C-12), 125.4 (C-4), 127.2 (C-9b), 135.8 (C-14a), 135.9 (C-13a), 136.5 (C-14c), 142.3 (C-1), 147.4 (C-3), 147.6 (C-4a) ppm. IR (NaCl): ν = 2942, 3182 cm⁻¹. HRMS calcd. for C₂₀H₂₀N₃O [M + H]⁺: 318.1601; found: 318.1601.

Data for 4: Yellow oil. [α]_D²² = -1.5 (*c* = 1.0, MeOH). ¹H NMR (400 MHz, CDCl₃, COSY, HSQC, 25 °C): δ = 2.03 (s, 3H, CH₃), 2.63 (d, *J* = 8.8 Hz, 1H, H-9), 2.64 (masked, 1H, H-9), 2.67–2.69 (m, 1H, H-5), 2.72 (dd, *J* = 9.6, 3.2 Hz, 1H, H-6), 3.00–3.14 (m, 2H,

H-5, H-6), 3.79 (dd, $J = 10.8, 5.2$ Hz, 1H, CH₂OH), 3.87 (t, $J = 10.8$ Hz, 1H, CH₂OH), 4.06 (m, 1H, H-8), 7.06 (masked d, $J = 4.8$ Hz, 1H, H-4), 7.09 (td, $J = 7.2, 1.2$ Hz, 1H, H-11), 7.14 (td, $J = 7.2, 1.2$ Hz, 1H, H-12), 7.29 (d, $J = 7.2$ Hz, 1H, H-10), 7.45 (d, $J = 7.2$ Hz, 1H, H-13), 8.36 (d, $J = 5.2$ Hz, 2H, H-3), 9.08 (s, 1H, H-1) ppm. NOESY 1D: positive NOE effect: 1-Me/3-H. ¹³C NMR (100.6 MHz, CDCl₃, 25 °C): $\delta = 19.6$ (C-9), 29.6 (C-5), 29.9 (CH₃), 36.2 (C-6), 53.9 (C-8), 58.7 (C-14b), 61.4 (CH₂O), 105.9 (C-9a), 111.2 (C-13), 118.2 (C-10), 119.7 (C-11), 122.1 (C-12), 124.2 (C-4), 127.1 (C-9b), 136.2 (C-13a), 136.8 (C-14a), 137.1 (C-14c), 144.5 (C-4a), 147.3 (C-3), 147.8 (C-1) ppm. IR (NaCl): $\nu = 1600, 3273$ cm⁻¹. HRMS calcd. for C₂₀H₂₂N₃O [M + H]⁺: 320.1757; found: 320.1763.

Treatment of 2 with Lawesson's Reagent: Lawesson's reagent (210 mg, 0.52 mmol) was added to a solution of lactams **2** and 10b-*epi-2* (150 mg, 0.45 mmol) in DME (2.7 mL). The resulting mixture was heated at reflux for 12 h, cooled, and concentrated. The resulting dark orange residue was dissolved in CH₂Cl₂, and the organic solution was washed twice with saturated aqueous NaHCO₃ solution. The organic layer was dried, filtered, and concentrated. Flash chromatography (1:4 hexane/EtOAc) afforded **5** (120 mg, 81%) as a yellow oil: $[\alpha]_D^{22} = -1.8$ ($c = 0.5$, CHCl₃). ¹H NMR (400 MHz, CDCl₃, COSY, HSQC, 25 °C): $\delta = 1.69$ (s, 3H, CH₃), 2.91 (dd, $J = 13.5, 10.5$ Hz, 1H, CH₂S), 3.08 (m, 2H, H-9), 3.45 (dd, $J = 13.5, 6.0$ Hz, 1H, CH₂S), 4.39 (m, 1H, H-8), 5.46 (s, 1H, H-5), 6.67 (d, $J = 4.8$ Hz, 1H, H-4), 7.09 (m, 2H, H-11 and H-12), 7.41 (d, $J = 7.6$ Hz, 1H, H-13), 7.49 (d, $J = 7.6$ Hz, 1H, H-10), 8.08 (d, $J = 4.4$ Hz, 1H, H-3), 8.98 (s, 1H, H-1), 11.82 (br. s, 1H, NH) ppm. NOESY 1D: positive NOE effect: 8-H/14b-Me. ¹³C NMR (75.4 MHz, CDCl₃, 25 °C): $\delta = 23.6$ (CH₃), 27.3 (C-9), 33.7 (CH₂S), 59.9 (C-14b), 60.3 (C-8), 90.6 (C-5), 106.9 (9a), 111.9 (C-13), 115.8 (C-4), 117.8 (C-10), 119.2 (C-11), 121.9 (C-12), 125.1 (C-9b), 126.0 (C-14a), 134.5 (C-13a), 137.6 (C-14c), 142.5 (C-1), 143.4 (C-4a), 146.4 (C-3), 153.5 (C-6) ppm. IR (NaCl): $\nu = 1467, 1572, 2926$ cm⁻¹. HRMS calcd. for C₂₀H₁₈N₃S [M + H]⁺: 332.1216; found: 332.1214.

(3S,8aR)-3-(3-Indolylmethyl)-8a-methyl-5-oxo-2,3,6,7,8,8a-hexahydro-5H-oxazolo[3,2-a]pyridine (6):

Method A: (S)-Tryptophanol (292 mg, 1.5 mmol) was added to a solution of 5-oxohexanoic acid (200 mg, 1.5 mmol) in toluene (23 mL). The mixture was heated at reflux for 23 h with azeotropic elimination of water by a Dean-Stark apparatus. The mixture was cooled and concentrated. Flash chromatography of the residue (2:8 hexane/EtOAc) afforded a mixture of lactams **6** and 8a-*epi-6* (340 mg, 80%; 87:13 by GC-MS) as a light yellow foam and 50 mg of **9** (11%).

Method B: (S)-Tryptophanol (70 mg, 0.38 mmol) and 5-oxohexanoic acid (50 mg, 0.38 mmol) in toluene (3 mL) were mixed in a capped 10 mL microwave vessel. The mixture was heated at 110 °C (average effective ramp time = 1 min). The power was set at 100 W and the pressure was set at 15 bar for 10 min. The solvent was evaporated, and the residue was dissolved in CH₂Cl₂. The organic phase was washed with 1 N aqueous HCl and saturated aqueous NaHCO₃ solutions, dried, filtered, and evaporated to afford a mixture of **6** and 8a-*epi-6* (83 mg, 77%; 92:8 calculated by ¹H NMR).

Data for 6 (from the mixture): ¹H NMR (400 MHz, CDCl₃, COSY, HSQC, 25 °C): $\delta = 1.31$ (s, 3H, CH₃), 1.56 (td, $J = 13.0, 4.0$ Hz, 1H, H-8), 1.69-1.83 (m, 1H, H-7), 1.84-1.98 (m, 1H, H-7), 2.06 (dt, $J = 13.0, 3.6$ Hz, 1H, H-8), 2.38 (ddd, $J = 18.4, 10.0, 8.0$ Hz, 1H, H-6), 2.54 (dd, $J = 18.4, 8.0$ Hz, 1H, H-6), 2.91 (dd, $J = 14.0, 10.4$ Hz, 1H, CH₂), 3.55 (ddd, $J = 14.0, 3.2, 0.8$ Hz, 1H, CH₂), 3.85 (dd, $J = 8.5, 7.6$ Hz, 1H, H-2), 3.98 (dd, $J = 8.5, 7.5$ Hz, 1H, H-2), 4.58 (m, 1H, H-3), 6.98 (d, $J = 1.6$ Hz, 1H, H-2'), 7.10 (td, $J = 8.0, 1.2$ Hz, 1H, H-5'), 7.17 (td, $J = 7.6, 1.2$ Hz, 1H, H-6'), 7.33 (d, $J = 7.6$ Hz, 1H, H-7'), 7.77 (d, $J = 8.0$ Hz, 1H, H-4'), 8.61 (br. s, 1H, NH) ppm. ¹³C NMR (100.6 MHz, CDCl₃, 25 °C): $\delta = 16.9$ (C-7), 23.7 (CH₃), 29.4 (CH₂), 30.4 (C-6), 34.9 (C-8), 55.9 (C-3), 68.0 (C-2), 93.2 (C-8a), 111.1 (C-7'), 111.5 (C-3'), 119.1 (C-4'), 119.3 (C-5'), 121.9 (C-6'), 122.2 (C-2'), 127.5 (C-3a'), 136.2 (C-7a'), 169.2 (CO) ppm. IR (NaCl): $\nu = 1626, 3284$ cm⁻¹. HRMS calcd. for C₁₇H₂₁N₂O₂ [M + H]⁺: 285.1598; found: 285.1596.

Data for 8a-epi-6 (from an enriched mixture): ¹H NMR (400 MHz, CDCl₃, 25 °C): $\delta = 1.34$ (s, 3H, CH₃), 1.64 (dd, $J = 12.5, 6.8$ Hz, 1H, H-8), 1.79-1.98 (m, 2H, H-7), 2.11 (ddd, $J = 12.5, 5.6, 2.8$ Hz, 1H, H-8), 2.43-2.50 (m, 2H, H-6), 2.67 (dd, $J = 13.8, 10.0$ Hz, 1H, CH₂), 3.78 (ddd, $J = 13.8, 2.9, 0.8$ Hz, 1H, CH₂), 3.95 (br. s, 1H, H-2), 3.96 (br. s, 1H, H-2), 4.35 (m, 1H, H-3), 7.01 (d, $J = 2.4$ Hz, 1H, H-2'), 7.12 (td, $J = 8.0, 1.2$ Hz, 1H, H-5'), 7.18 (td, $J = 8.0, 1.2$ Hz, 1H, H-6'), 7.34 (d, $J = 7.6$ Hz, 1H, H-7'), 7.81 (d, $J = 8.0$ Hz, 1H, H-4'), 8.29 (br. s, 1H, NH) ppm. ¹³C NMR (100.6 MHz, CDCl₃, 25 °C): $\delta = 16.7$ (C-7), 22.9 (CH₃), 26.6 (CH₂), 29.6 (C-6), 34.6 (C-8), 56.3 (C-3), 67.3 (C-2), 93.2 (C-8a), 111.0 (C-7'), 112.5 (C-3'), 119.3 (C-4'), 119.5 (C-5'), 122.1 (C-6'), 122.3 (C-2'), 127.7 (C-3a'), 136.2 (C-7a'), 168.4 (CO) ppm. IR (NaCl): $\nu = 1626, 3284$ cm⁻¹. HRMS calcd. for C₁₇H₂₁N₂O₂ [M + H]⁺: 285.1598; found: 285.1596.

(4S,6S,12bS)-4,6-(Epoxy-methano)-4-methyl-1,2,3,4,6,7,12,12b-octahydroindolo[2,3-a]quinolizine (7): Lawesson's reagent (384 mg, 0.95 mmol) was added to a solution of lactams **6** and 8a-*epi-6* (300 mg, 1.1 mmol) in DME (10 mL). The resulting mixture was heated at reflux for 4.5 h, cooled, and concentrated to give a dark brown residue, which was dissolved in EtOAc. The solution was washed twice with saturated aqueous NaHCO₃. The organic layer was dried, filtered, and concentrated to give 400 mg of a yellow foam. Flash chromatography (hexane to 8:2 hexane/EtOAc) gave a mixture of thiolactams (179 mg, 54%; 9:1 by GC-MS) as a white solid: ¹H NMR (400 MHz, CDCl₃, COSY, HSQC, 25 °C, major epimer): $\delta = 1.42$ (s, 3H, CH₃), 1.67 (dd, $J = 12.5, 5.8$ Hz, 1H, H-8), 1.70-1.82 (m, 1H, H-7), 1.84-1.95 (m, 1H, H-7), 2.03-2.14 (m, 1H, H-8), 2.94 (dd, $J = 13.7, 10.7$ Hz, 1H, H-6), 3.07-3.13 (m, 2H, H-6, CH₂), 3.57-4.18 (m, 3H, CH₂, H-2), 4.92-5.19 (m, 1H, H-3), 7.05 (d, $J = 1.9$ Hz, 1H, H-2'), 7.12-7.18 (m, 1H, H-5'), 7.19-7.25 (m, 1H, H-6'), 7.35 (d, $J = 7.8$ Hz, 1H, H-7'), 7.99 (d, $J = 7.8$ Hz, 1H, H-4'), 8.24 (br. s, 1H, NH) ppm. ¹³C NMR (100.6 MHz, CDCl₃, 25 °C): $\delta = 16.8$ (C-7), 22.9 (CH₃), 27.7 (CH₂), 34.1 (C-6), 39.6 (C-8), 61.1 (C-3), 67.1 (C-2), 94.6 (C-8a), 111.0 (C-7'), 111.3 (C-3'), 119.5 (C-4'), 119.6 (C-5'), 122.1 (C-6'), 122.3 (C-2'), 127.4 (C-3a'), 136.1 (C-7a'), 197.0 (CO) ppm. BnBr (134 μ L, 1.13 mmol) was added to a solution, kept in the dark, of the above thiolactams (170 mg, 0.57 mmol) in CH₃CN (4.5 mL), and the resulting mixture was heated at 60 °C for 48 h. The solvent was removed under reduced pressure, and the dark yellow residue was dissolved in MeOH (15 mL). Then, NaBH₄ (65 mg, 1.71 mmol) was added at

-78 °C, and the mixture was allowed to reach room temperature and stirred for 4.5 h. Acetone (0.5 mL) was added, and the solvent was evaporated. The resulting residue was dissolved in CH₂Cl₂, and the solution was washed with brine. The organic phase was dried and concentrated to give a yellow oil (300 mg), which was chromatographed (7:3 hexane/EtOAc) to afford **7** (78 mg, 51%) as a yellow oil: [α]_D²² = -109.1 (*c* = 0.7, CHCl₃). ¹H NMR (400 MHz, CDCl₃, COSY, HSQC, 25 °C): δ = 1.20 (s, 3H, CH₃), 1.46 (m, 1H, H-2), 1.62 (m, 2H, H-1, H-3), 1.93 (m, 2H, H-1, H-3), 2.05 (m, 1H, H-2), 2.58 (ddd, *J* = 14.4, 10.0, 2.4 Hz, 1H, H-7), 3.01 (ddd, *J* = 14.4, 4.4, 1.6 Hz, 1H, H-7), 3.32 (m, 1H, H-6), 3.72 (t, *J* = 7.5 Hz, 1H, CH₂O), 3.84 (br. dd, *J* = 10.8, 1.6 Hz, 1H, H-12b), 4.23 (t, *J* = 7.5 Hz, 1H, CH₂O), 7.09 (dd, *J* = 7.2, 1.2 Hz, 1H, H-9), 7.14 (dd, *J* = 7.2, 1.2 Hz, 1H, H-10), 7.31 (d, *J* = 7.2 Hz, 1H, H-11), 7.47 (d, *J* = 7.2 Hz, 1H, H-8), 7.88 (br. s, 1H, NH) ppm. NOESY 1D: positive NOE effects: 4-Me/6-H, 4-Me/12b-H, and 6-H/12b-H. ¹³C NMR (100.6 MHz, CDCl₃, 25 °C): δ = 13.9 (CH₃), 21.9 (C-2), 26.2 (C-7), 30.8 (C-1), 36.6 (C-3), 51.3 (C-12b), 52.5 (C-6), 70.3 (CH₂O), 91.5 (C-4), 107.7 (C-7a), 110.7 (C-11), 118.0 (C-8), 119.4 (C-9), 121.4 (C-10), 127.2 (C-7b), 135.5 (C-12a), 136.5 (C-11a) ppm. IR (NaCl): ν = 3267 cm⁻¹. HRMS calcd. for C₁₇H₂₁N₂O [M + H]⁺: 269.1648; found: 269.1644.

Treatment of 6 under Bischler–Napieralski conditions: POCl₃ (500 μ L, 5.5 mmol) was added to a solution of lactams **6** and *epi-6* (100 mg, 0.35 mmol) in toluene (5 mL), and the mixture was heated at 100 °C for 2 h. After cooling, the solvent was removed, and the brown residue was dissolved in anhydrous MeOH (7 mL). Then, NaBH₄ (excess, until basic pH) was slowly added to the solution at 0 °C, and the mixture was allowed to reach room temperature and stirred for 3 h. After cooling at 0 °C, the mixture was quenched with H₂O and extracted with EtOAc. The organic layer was washed with brine, dried, and concentrated to give an oil (114 mg). Flash chromatography (8:2 hexane/EtOAc to 95:5 EtOAc/MeOH) gave pentacycle **7** (31 mg, 33%), tetracycle **9** (6 mg, 6%) and tetracycle **8** (14 mg, 19%).

NaBH₄ reduction of 7: NaBH₄ (85 mg, 2.25 mmol) was slowly added (0 °C) to a solution of **7** (120 mg, 0.45 mmol) in MeOH (10 mL), and the suspension was stirred at room temperature for 1 h. The mixture was cooled at 0 °C, quenched with H₂O, and extracted with CH₂Cl₂. The combined organic extracts were washed with brine, dried, and concentrated to give a yellow oil which was chromatographed (EtOAc) affording tetracycle **8** (108 mg, 90%).

Data for 8: Light yellow oil. [α]_D²² = +36.5 (*c* = 1.1, CHCl₃). ¹H NMR (400 MHz, CDCl₃, COSY, HSQC, 25 °C): δ = 1.21 (d, *J* = 6.8 Hz, 3H, CH₃), 1.30-1.39 (m, 1H, H-3), 1.40-1.52 (m, 1H, H-2), 1.56-1.67 (m, 2H, H-1, H-3), 1.81-1.97 (m, 2H, H-1, H-2), 2.76 (dd, *J* = 15.0, 5.2 Hz, 1H, H-7), 2.96 (dd, *J* = 15.0, 3.1 Hz, 1H, H-7), 3.14-3.24 (m, 1H, H-4), 3.49 (dd, *J* = 9.6, 8.4 Hz, 1H, CH₂O), 3.53-3.64 (m, 2H, H-12b, CH₂O), 4.01 (br. d, *J* = 9.2 Hz, 1H, H-6), 7.08 (td, *J* = 7.6, 1.2 Hz, 1H, H-10), 7.13 (td, *J* = 7.6, 1.2 Hz, 1H, H-9), 7.30 (d, *J* = 7.6 Hz, 1H, H-8), 7.47 (d, *J* = 7.1 Hz, 1H, H-11), 7.80 (br. s, 1H, NH) ppm. NOESY 1D: positive NOE effect: 4-H/6-H. ¹³C NMR (100.6 MHz, CDCl₃, 25 °C): δ = 20.0 (CH₃), 23.2 (C-7), 23.3 (C-1), 30.3 (C-2), 33.8 (C-3), 54.5 (C-4), 54.9 (C-12b), 54.7 (C-6), 64.2 (CH₂O), 107.1 (C-7a), 110.0 (C-8), 118.1 (C-11), 119.3 (C-10), 121.2 (C-9), 127.7 (C-7b), 135.5 (C-12a), 135.9 (C-

11a) ppm. IR (NaCl): ν = 1453, 3257 cm⁻¹. HRMS calcd. for C₁₇H₂₂N₂O [M + H]⁺: 271.1805; found: 271.1807.

(6*S*,12*bR*)-6-(Hydroxymethyl)-12*b*-methyl-4-oxo-1,2,3,4,6,7,12,12*b*-octahydroindolo[2,3-*a*]quinolizine (9): TFA (0.9 M solution in CH₂Cl₂, 4 mL) was added to a solution of lactams **6** and *epi-6* (100 mg, 0.35 mmol) in CH₂Cl₂ (2 mL), and the resulting mixture was stirred at room temperature for 20 h. The solvent was removed under reduced pressure, and the residue was dissolved in CH₂Cl₂ (6 mL). Then, KOH (150 mg, 2.7 mmol) was added, and the suspension was stirred at room temperature for 20 h. The resulting mixture was diluted with CH₂Cl₂ and washed twice with water. The organic layer was dried, filtered, and concentrated. Flash chromatography (8:2 hexane/EtOAc to EtOAc) gave tetracycle **9** (66 mg, 66%) and 12*b-epi-9* (20 mg, 20%).

Data for 9: Brown solid. [α]_D²² = +132.6 (*c* = 0.9, MeOH). ¹H NMR (CD₃OD, 400 MHz, COSY, HSQC, 25 °C): δ = 1.67 (s, 3H, CH₃), 1.80 (td, *J* = 13.6, 4.6 Hz, 1H, H-1), 1.99-1.85 (m, 1H, H-2), 2.25-2.05 (m, 1H, H-2), 2.35 (dt, *J* = 13.3, 3.2 Hz, 1H, H-1), 2.54 (ddd, *J* = 18.5, 9.7, 9.0 Hz, 1H, H-3), 2.67 (dd, *J* = 18.5, 7.5 Hz, 1H, H-3), 2.81 (dd, *J* = 15.8, 6.2 Hz, 1H, H-7), 3.04 (dd, *J* = 15.8, 1.1 Hz, 1H, H-7), 3.54 (dd, *J* = 10.3, 6.1 Hz, 1H, CH₂O), 3.62 (dd, *J* = 10.3, 8.9 Hz, 1H, CH₂O), 5.45 (dd, *J* = 8.9, 6.1 Hz, 1H, H-6), 7.03 (ddd, *J* = 8.0, 7.1, 1.0 Hz, 1H, H-10), 7.11 (ddd, *J* = 8.2, 7.1, 1.2 Hz, 1H, H-9), 7.33 (d, *J* = 8.1 Hz, 1H, H-8), 7.46 (d, *J* = 7.6 Hz, 1H, H-11) ppm. ¹³C NMR (CD₃OD, 100.6 MHz, 25 °C): δ = 16.8 (C-2), 21.9 (C-7), 27.6 (CH₃), 31.4 (C-3), 38.2 (C-1), 50.7 (C-6), 57.3 (C-12b), 63.8 (CH₂O), 104.4 (C-7a), 111.9 (C-11), 118.9 (C-8), 119.9 (C-10), 122.5 (C-9), 128.1 (C-7b), 137.9 (C-12a), 138.3 (C-11a), 173.1 (CO) ppm. IR (NaCl): ν = 1609, 3268 cm⁻¹. HRMS calcd. for C₁₇H₂₁N₂O₂ [M + H]⁺: 285.1598; found: 285.1593.

Data for 12*b-epi-9*: [α]_D²² = -168.8 (*c* = 1.0, MeOH). ¹H NMR (400 MHz, CD₃OD, 25 °C): δ = 1.74 (s, 3H, CH₃), 1.75-1.84 (m, 1H, H-2), 1.88-2.06 (m, 1H, H-1, H-2), 2.30-2.47 (m, 2H, H-1, H-3), 2.52-2.62 (m, 1H, H-3), 2.84 (dd, *J* = 15.0, 3.1 Hz, 1H, H-7), 3.07 (dd, *J* = 15.0, 8.7 Hz, 1H, H-7), 3.90-4.05 (m, 3H, H-6, CH₂O), 7.02 (ddd, *J* = 8.0, 7.1, 1.2 Hz, 1H, H-10), 7.09 (ddd, *J* = 8.0, 7.1, 1.2 Hz, 1H, H-9), 7.32 (d, *J* = 8.0 Hz, 1H, H-8), 7.44 (d, *J* = 7.8 Hz, 1H, H-11) ppm. ¹³C NMR (100.6 MHz, CD₃OD, 25 °C): δ = 17.6 (C-2), 23.7 (C-7), 27.2 (CH₃), 33.9 (C-3), 36.5 (C-1), 59.4 (C-6), 61.1 (C-12b), 64.3 (CH₂O), 108.5 (C-7a), 112.1 (C-11), 118.8 (C-8), 120.0 (C-10), 122.4 (C-9), 127.9 (C-7b), 137.9 (C-12a), 140.1 (C-11a), 174.4 (CO) ppm. IR (NaCl): ν = 1613, 3268 cm⁻¹. HRMS calcd. for C₁₇H₂₁N₂O₂ [M + H]⁺: 285.1598; found: 285.1597.

Data for 10: [α]_D²² = +160.9 (*c* = 1.0, CHCl₃). ¹H NMR (400 MHz, CDCl₃, COSY, HSQC, 25 °C): δ = 1.71 (s, 3H, CH₃), 1.85 (td, *J* = 13.0, 4.6 Hz, 1H, H-1), 1.90-1.99 (m, 1H, H-2), 2.03-2.21 (m, 1H, H-2), 2.27 (d, *J* = 13.0 Hz, 1H, H-1), 2.61 (dt, *J* = 18.5, 9.5 Hz, 1H, H-3), 2.74 (dd, *J* = 18.5, 7.5 Hz, 1H, H-3), 2.95 (dd, *J* = 16.0, 6.2 Hz, 1H, H-7), 3.10 (dd, *J* = 16.0, 1.0 Hz, 1H, H-7), 3.55 (dd, *J* = 10.5, 6.7 Hz, 1H, CH₂Cl), 3.62 (dd, *J* = 10.5, 8.7 Hz, 1H, CH₂Cl), 5.72 (dd, *J* = 14.1, 6.8 Hz, 1H, H-6), 7.11-7.17 (m, 1H, H-10), 7.17-7.23 (m, 1H, H-9), 7.36 (d, *J* = 8.0 Hz, 1H, H-8), 7.53 (d, *J* = 7.8 Hz, 1H, H-11), 8.86 (br. s, 1H, NH) ppm. ¹³C NMR (100.6 MHz, CDCl₃, 25 °C): δ = 16.0 (C-2), 22.2 (C-7), 27.7 (CH₃), 30.7 (C-3), 37.7 (C-1), 45.5 (C-6), 48.7 (CH₂Cl), 55.7 (C-12b), 104.1

(C-7a), 111.0 (C-11), 118.4 (C-8), 119.6 (C-10), 122.2 (C-9), 126.8 (C-7b), 136.2 (C-12a), 136.6 (C-11a), 170.7 (CO) ppm. IR (NaCl): $\nu = 1397, 1611, 3268 \text{ cm}^{-1}$. HRMS calcd. for $\text{C}_{17}\text{H}_{20}\text{ClN}_2\text{O}_2$ [M + H]⁺: 303.1259; found: 303.1251.

Acknowledgments


Financial support from the Spanish Ministries of Science and Innovation (Project CTQ2009-07021/BQU) and Economy and Competitiveness (Project CTQ2012-35250), and the AGAUR, Generalitat de Catalunya (Grant 2009-SGR-1111) is gratefully acknowledged.

- [1] For reviews, see: a) M. Amat, M. Pérez, J. Bosch, *Synlett* **2011**, 143–160; b) M. M. M. Santos in: *Heterocyclic Targets in Advanced Organic Synthesis* (Eds.: M. do C. Carreiras, J. Marco-Contelles), Research Signpost, Kerala, India, **2011**, pp. 69–82. See also: c) S. M. Allin, C. I. Thomas, K. Doyle, M. R. J. Elsegood, *J. Org. Chem.* **2005**, *70*, 357–359; d) S. M. Allin, J. S. Khera, J. Witherington, M. R. J. Elsegood, *Tetrahedron Lett.* **2006**, *47*, 5737–5739; e) M. Amat, A. Gómez-Esqué, C. Escolano, M. M. M. Santos, E. Molins, J. Bosch, *J. Org. Chem.* **2009**, *74*, 1205–1211.
- [2] a) S. M. Allin, C. I. Thomas, J. E. Allard, K. Doyle, M. R. J. Elsegood, *Tetrahedron Lett.* **2004**, *45*, 7103–7105; b) O. Bassas, N. Llor, M. M. M. Santos, R. Grieria, E. Molins, M. Amat, J. Bosch, *Org. Lett.* **2005**, *7*, 2817–2820; c) M. Amat, M. M. M. Santos, O. Bassas, N. Llor, C. Escolano, A. Gómez-Esqué, E. Molins, S. M. Allin, V. McKee, J. Bosch, *J. Org. Chem.* **2007**, *72*, 5193–5201; d) S. M. Allin, L. J. Duffy, P. C. Bulman Page, V. McKee, M. J. McKenzie, *Tetrahedron Lett.* **2007**, *48*, 4711–4714; e) S. M. Allin, L. J. Duffy, J. M. R. Towler, P. C. Bulman Page, M. R. J. Elsegood, B. Saha, *Tetrahedron* **2009**, *65*, 10230–10234.
- [3] M. Amat, L. Navío, N. Llor, E. Molins, J. Bosch, *Org. Lett.* **2012**, *14*, 210–213.
- [4] M. Amat, M. M. M. Santos, A. M. Gómez, D. Jokic, E. Molins, J. Bosch, *Org. Lett.* **2007**, *9*, 2907–2910.
- [5] M. Pérez, F. Arioli, G. Rigacci, M. M. M. Santos, A. Gómez-Esqué, C. Escolano, P. Florindo, C. Ramos, J. Bosch, M. Amat, *Eur. J. Org. Chem.* **2011**, 3858–3863.
- [6] a) Isolation: G. Massiot, P. Thépenier, M.-J. Jacquier, L. Le Men-Olivier, R. Verpoorte, C. Delaude, *Phytochemistry* **1987**, *26*, 2839–2846; b) Absolute configuration: D. Arbain, D. P. Putra, M. V. Sargent, *Aust. J. Chem.* **1993**, *46*, 977–985; c) First enantioselective synthesis: M. Ohba, H. Kubo, T. Fujii, H. Ishibashi, M. V. Sargent, D. Arbain, *Tetrahedron Lett.* **1997**, *38*, 6697–6700.
- [7] For precedents, see ref.^[1c,e,2a,2c,4]
- [8] Minor amounts of 10b-*epi*-2 were also detected (ratio 2:10b-*epi*-2 96:4). Cyclocondensation reactions of phenylglycinol with δ -keto esters lead to oxazolopiperidone lactams with a *trans*-relationship between the methine proton and the angular substituent of the oxazolidine ring: M. Amat, O. Bassas, N. Llor, M. Cantó, M. Pérez, E. Molins, J. Bosch, *Chem. Eur. J.* **2006**, *12*, 7872–7881.
- [9] For reviews on the chemistry and cyclizations of *N*-acyl iminium ions, see: a) W. N. Speckamp, M. J. Moolenaar, *Tetrahedron* **2000**, *56*, 3817–3856; b) B. E. Maryanoff, H.-C. Zhang, J. H. Cohen, I. J. Turchi, C. A. Maryanoff, *Chem. Rev.* **2004**, *104*, 1431–1628.
- [10] For the generation of related oxazolinium salts by treatment of aminoalcohol-derived lactams with POCl_3 or POBr_3 , see: a) A. Castro, J. Ramírez, J. Juárez, J. L. Terán, L. Orea, A. Galindo, D. Gnecco, *Heterocycles* **2007**, *71*, 2699–2708; b) D. Gnecco, A. M. Lumbreras, J. L. Terán, A. Galindo, J. R. Juárez, M. L. Orea, A. Castro, R. G. Enríquez, W. F. Reynolds, *Heterocycles* **2009**, *78*, 2589–2594; c) see also ref.^[5]
- [11] For reviews, see: a) M. Lounasmaa, M. Berner, A. Tolvanen, *Heterocycles* **1998**, *48*, 1275–1290; b) M. Lounasmaa, M. Berner, M. Brunner, H. Suomalainen, A. Tolvanen, *Tetrahedron* **1998**, *54*, 10205–10216.
- [12] The kinetically controlled product in α -amidoalkylation reactions from tryptophan-derived lactams possesses a *trans* relative stereochemistry between the methine proton of the tryptophan moiety and the angular substituent at C-12b (indolo[2,3-*a*]quinolizidine numbering): see ref.^[1c,d,2,5]
- [13] P. Deslongchamps, *Stereoelectronic Effects in Organic Chemistry*; Pergamon Press, Oxford, **1983**, p. 221.
- [14] For precedents for the direct conversion of alcohols into thiols involving the nucleophilic attack of the alcohol to the monomeric species of Lawesson's reagent present in solution to form an *O*-alkyl phosphonodithioic acid intermediate, see: T. Nishio, *J. Chem. Soc., Perkin Trans I* **1993**, 1113–1117.
- [15] Minor amounts (~10%) of indoloquinolizidine **9** were also formed. A similar cyclocondensation from 4-oxopentanoic acid has been reported to give the corresponding indoloindolizidine as the main product by a mechanism that involves an initial Pictet-Spengler cyclization leading to a tetrahydro- β -carboline derivative, which undergoes a final lactamization: S. M. Allin, C. I. Thomas, J. E. Allard, M. Duncton, M. R. J. Elsegood, M. Edgar, *Tetrahedron Lett.* **2003**, *44*, 2335–2337.
- [16] For the generation of aminoalcohol-derived oxazolopiperidone lactams using the microwave-assisted procedure, see: M. Jida, R. Deprez-Poulain, S. Malaquin, P. Roussel, F. Agbossou-Niedercorn, B. Deprez, G. Laconde, *Green Chem.* **2010**, *12*, 961–964.
- [17] Minor amounts (~5%) of the α -amidoalkylation product **10**, in which the substitution of the hydroxyl group by chloride has also occurred, were detected from the crude mixture.
- [18] Minor amounts of the epimer 4-*epi*-8 were detected by GC-MS (93:7 ratio).
- [19] CCDC-909407 (for **9**) and CCDC-909408 (for 12b-*epi*-9) contain the supplementary crystallographic data for this paper. These data can be obtained free of charge from The Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif.
- [20] For related cyclizations where a substituent α to the amide nitrogen acts as an element of stereocontrol, see: a) B. E. Maryanoff, D. F. McComsey, H. R. Almond Jr., M. S. Mutter, G. W. Bemis, R. R. Whittle, R. A. Olofson, *J. Org. Chem.* **1986**, *51*, 1341–1346; b) R. H. Huizenga, U. K. Pandit, *Tetrahedron* **1992**, *48*, 6521–6528; c) S. M. Allin, S. L. James, W. P. Martin, T. A. D. Smith, M. R. J. Elsegood, *J. Chem. Soc., Perkin Trans I* **2001**, 3029–3036; d) A. Ardeo, E. García, S. Arrasate, E. Lete, N. Sotomayor, *Tetrahedron Lett.* **2003**, *44*, 8445–8448; e) T. E. Nielsen, M. Meldal, *J. Org. Chem.* **2004**, *69*, 3765–3773; f) E. García, S. Arrasate, E. Lete, N. Sotomayor, *J. Org. Chem.* **2005**, *70*, 10368–10374. See also ref.^[1c,2]
- [21] F. Bracher, K. Mink, *Liebigs Ann.* **1995**, 645–647.

Received: ((will be filled in by the editorial staff))
Published online: ((will be filled in by the editorial staff))

Entry for the Table of Contents

Layout 2:



Cyclizations on the lactam carbonyl from tryptophan-derived oxazolopiperidone lactams are studied. A pyridine ring fused to the piperidone moiety exerts

a dramatic effect on the regioselectivity of the cyclization, exclusively leading to α-amidoalkylation products.

((Key Topic))

M. Amat,* N. Llor, F. Subrizi, M. Pérez, E. Molins, and J. Bosch
Page No. – Page No.


Studies on the Regioselectivity of the Cyclization of Tryptophan-Derived Oxazolopiperidone Lactams.

Keywords: Lactams / Asymmetric synthesis / Cyclization / Bischler–Napieralski / α-Amidoalkylation

Supporting Information


NMR- ^1H /Mercury-400

T = 25 °C/ CDCl_3




NMR- ^{13}C /Mercury-400

T = 25 °C/ CDCl_3




NMR-H¹/Mercury-400

T = 25 °C/CDCl₃




NMR-H¹/Mercury-400

T = 25 °C/CDCl₃




NMR-C¹³/Mercury-400

T = 25 °C/CDCl₃




NMR- ^1H /Mercury-400

T = 25 °C/ CDCl_3




NMR- ^{13}C /Mercury-400


T = 25 °C/ CDCl_3



NMR- ^1H /Mercury-400
T = 25 °C/ CDCl_3




NMR- ^{13}C /Gemini-300
T = 25 °C/ CDCl_3




NMR- ^1H /Mercury-400

T = 25 °C/ CDCl_3




NMR- ^{13}C /Mercury-400

T = 25 °C/ CDCl_3




NMR-H¹/Mercury-400

T = 25 °C/CDCl₃




NMR-C¹³/Mercury-400

T = 25 °C/CDCl₃




NMR-H¹/Mercury-400

T = 25 °C/CDCl₃




NMR-C¹³/Mercury-400


T = 25 °C/CDCl₃



NMR- ^1H /Mercury-400
T = 25 °C/ CDCl_3




NMR- ^{13}C /Mercury-400
T = 25 °C/ CDCl_3




NMR- ^1H /Mercury-400

T = 25 °C/ CDCl_3




NMR- ^{13}C /Mercury-400


T = 25 °C/ CDCl_3



NMR- ^1H /Mercury-400
T = 25 °C/ CD₃OD




NMR- ^{13}C /Mercury-400
T = 25 °C/ CD₃OD




NMR-H¹/Mercury-400

T = 25 °C/CD₃OD




NMR-C¹³/Mercury-400

T = 25 °C/ CD₃OD




NMR-¹H/Mercury-400

T = 25 °C/CDCl₃




NMR-¹³C/Mercury-400

T = 25 °C/CDCl₃




Crystal data and structure refinement for compound 9



Identification code	Jb88
Empirical formula	C ₁₇ H ₂₀ N ₂ O ₂
Formula weight	284.35
Temperature	293(2) K
Wavelength	0.71073 Å
Crystal system	Tetragonal
Space group	P 41 21 2
Unit cell dimensions	a = 10.0470(16) Å α = 90°. b = 10.0470(18) Å β = 90°. c = 28.929(6) Å γ = 90°.
Volume	2920.2(9) Å ³
Z	8
Density (calculated)	1.294 Mg/m ³
Absorption coefficient	0.086 mm ⁻¹
F(000)	1216
Crystal size	0.27 x 0.27 x 0.12 mm ³
Theta range for data collection	2.15 to 24.98°.
Index ranges	-7 ≤ h ≤ 8, 0 ≤ k ≤ 11, 0 ≤ l ≤ 34
Reflections collected	5841
Independent reflections	2566
Completeness to theta = 24.98°	100.0 %
Refinement method	Full-matrix least-squares on F ²
Data / restraints / parameters	2566 / 0 / 192
Goodness-of-fit on F ²	1.054
Final R indices [I > 2σ(I)]	R1 = 0.0428, wR2 = 0.0814
R indices (all data)	R1 = 0.0688, wR2 = 0.0893
Largest diff. peak and hole	0.124 and -0.118 e.Å ⁻³

Crystal data and structure refinement for compound 12b-*epi*-9



Jb89

C₁₇ H₂₀ N₂ O₂

284.35

294(2) K

0.71073 Å

Orthorhombic

P 21 21 21

Formula weight

Temperature

Wavelength

Crystal system

Space group

Unit cell dimensions

a = 10.164(2) Å α = 90°.

b = 10.178(4) Å β = 90°.

c = 14.373(4) Å γ = 90°.

Volume

1486.9(8) Å³

Z

4

Density (calculated)

1.270 Mg/m³

Absorption coefficient

0.084 mm⁻¹

F(000)

608

Crystal size

0.42 x 0.42 x 0.21 mm³

Theta range for data collection

2.45 to 26.97°.

Index ranges

0 ≤ h ≤ 12, 0 ≤ k ≤ 12, 0 ≤ l ≤ 18

Reflections collected

1982

Independent reflections

1848

Completeness to theta = 26.97°

100.0 %

Max. and min. transmission

0.9826 and 0.9656

Refinement method

Full-matrix least-squares on F²

Data / restraints / parameters

1848 / 0 / 192

Goodness-of-fit on F²

1.029

Final R indices [I > 2σ(I)]

R1 = 0.0410, wR2 = 0.0852

R indices (all data)

R1 = 0.0662, wR2 = 0.0935

Largest diff. peak and hole

0.133 and -0.139 e.Å⁻³